 Adam Corken
Concepts (123)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 7 | 2024 | 245 | 2.490 |
Why?
| | Thrombosis | 7 | 2024 | 249 | 1.980 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2024 | 168 | 1.630 |
Why?
| | Inflammation | 6 | 2024 | 604 | 1.230 |
Why?
| | Platelet Glycoprotein GPIb-IX Complex | 4 | 2024 | 49 | 1.010 |
Why?
| | P-Selectin | 1 | 2024 | 32 | 0.960 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2024 | 32 | 0.950 |
Why?
| | Receptors, Purinergic | 1 | 2024 | 12 | 0.950 |
Why?
| | Platelet Activation | 1 | 2024 | 46 | 0.940 |
Why?
| | Radiation Protection | 1 | 2021 | 48 | 0.790 |
Why?
| | Hemostasis | 4 | 2024 | 55 | 0.630 |
Why?
| | Sepsis | 2 | 2018 | 220 | 0.510 |
Why?
| | Mice, Inbred C57BL | 3 | 2024 | 1806 | 0.380 |
Why?
| | Animals | 7 | 2024 | 13150 | 0.310 |
Why?
| | Mice | 5 | 2024 | 5720 | 0.300 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 388 | 0.290 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2023 | 174 | 0.260 |
Why?
| | Signal Transduction | 4 | 2024 | 1617 | 0.260 |
Why?
| | Purinergic Antagonists | 1 | 2024 | 7 | 0.240 |
Why?
| | Albuminuria | 1 | 2022 | 47 | 0.210 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 20 | 0.190 |
Why?
| | Blood Vessels | 1 | 2020 | 72 | 0.180 |
Why?
| | Protein Binding | 1 | 2021 | 660 | 0.180 |
Why?
| | Humans | 12 | 2024 | 49827 | 0.170 |
Why?
| | Cytokines | 1 | 2022 | 612 | 0.170 |
Why?
| | Homeostasis | 1 | 2020 | 199 | 0.170 |
Why?
| | Platelet Membrane Glycoproteins | 1 | 2018 | 18 | 0.160 |
Why?
| | Haplotypes | 1 | 2018 | 83 | 0.160 |
Why?
| | Cyclin D1 | 1 | 2017 | 56 | 0.150 |
Why?
| | GTP Phosphohydrolases | 1 | 2017 | 31 | 0.140 |
Why?
| | von Willebrand Factor | 2 | 2014 | 42 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 66 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 79 | 0.140 |
Why?
| | Neutrophils | 2 | 2015 | 137 | 0.140 |
Why?
| | Obesity | 1 | 2024 | 1113 | 0.130 |
Why?
| | Translocation, Genetic | 1 | 2017 | 264 | 0.130 |
Why?
| | Male | 6 | 2024 | 25093 | 0.130 |
Why?
| | Membrane Proteins | 1 | 2017 | 342 | 0.120 |
Why?
| | Neoplasms | 2 | 2015 | 1233 | 0.120 |
Why?
| | Macrophage-1 Antigen | 1 | 2014 | 9 | 0.120 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 38 | 0.120 |
Why?
| | Ligation | 1 | 2014 | 59 | 0.120 |
Why?
| | Interleukin-4 | 1 | 2014 | 43 | 0.120 |
Why?
| | Cecum | 1 | 2014 | 63 | 0.120 |
Why?
| | Cell Communication | 1 | 2014 | 69 | 0.110 |
Why?
| | Endotoxemia | 1 | 2013 | 32 | 0.110 |
Why?
| | Ligands | 1 | 2014 | 204 | 0.110 |
Why?
| | Monocytes | 1 | 2014 | 132 | 0.110 |
Why?
| | Minerals | 1 | 1992 | 32 | 0.110 |
Why?
| | Legislation, Drug | 1 | 1992 | 17 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2013 | 55 | 0.110 |
Why?
| | Thrombocytopenia | 1 | 2013 | 84 | 0.110 |
Why?
| | Vitamins | 1 | 1992 | 64 | 0.110 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 240 | 0.100 |
Why?
| | Mice, Knockout | 1 | 2014 | 841 | 0.100 |
Why?
| | Time Factors | 2 | 2014 | 2912 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2014 | 1451 | 0.080 |
Why?
| | United States Food and Drug Administration | 2 | 2001 | 92 | 0.070 |
Why?
| | Platelet Aggregation | 1 | 2023 | 71 | 0.050 |
Why?
| | Adenosine | 1 | 2023 | 69 | 0.050 |
Why?
| | Ticlopidine | 1 | 2023 | 55 | 0.050 |
Why?
| | Multiple Myeloma | 1 | 2017 | 2910 | 0.050 |
Why?
| | Cisapride | 1 | 2001 | 3 | 0.050 |
Why?
| | Drug and Narcotic Control | 1 | 2001 | 10 | 0.050 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2001 | 17 | 0.050 |
Why?
| | Gastrointestinal Agents | 1 | 2001 | 34 | 0.050 |
Why?
| | Phospholipase C gamma | 1 | 2020 | 4 | 0.050 |
Why?
| | Meninges | 1 | 2020 | 13 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2020 | 30 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2001 | 93 | 0.050 |
Why?
| | Age of Onset | 1 | 2018 | 106 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2018 | 116 | 0.040 |
Why?
| | Retinoblastoma Binding Proteins | 1 | 2017 | 10 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 18 | 0.040 |
Why?
| | Skin | 1 | 2020 | 407 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 27 | 0.040 |
Why?
| | Female | 4 | 2023 | 26329 | 0.040 |
Why?
| | Codon | 1 | 2017 | 47 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2017 | 88 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 175 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 237 | 0.030 |
Why?
| | Phenotype | 1 | 2018 | 727 | 0.030 |
Why?
| | Disease Progression | 1 | 2018 | 822 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 510 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2018 | 942 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 202 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2018 | 1128 | 0.030 |
Why?
| | Tumor Escape | 1 | 2015 | 16 | 0.030 |
Why?
| | NF-kappa B | 1 | 2017 | 314 | 0.030 |
Why?
| | Anticarcinogenic Agents | 1 | 2015 | 34 | 0.030 |
Why?
| | Cell Death | 1 | 2015 | 181 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 231 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 268 | 0.030 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 103 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2015 | 161 | 0.030 |
Why?
| | Aspirin | 1 | 2015 | 114 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2017 | 234 | 0.030 |
Why?
| | Risk Factors | 2 | 2018 | 3619 | 0.030 |
Why?
| | Platelet Adhesiveness | 1 | 2013 | 13 | 0.030 |
Why?
| | DNA | 1 | 2017 | 545 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2013 | 182 | 0.030 |
Why?
| | Peptides | 1 | 2013 | 222 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 191 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2023 | 5138 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1031 | 0.030 |
Why?
| | Models, Biological | 1 | 2015 | 728 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2013 | 555 | 0.030 |
Why?
| | Prognosis | 1 | 2017 | 1952 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 254 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2018 | 2744 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 1293 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 1007 | 0.020 |
Why?
| | Infant | 1 | 2018 | 3551 | 0.020 |
Why?
| | Child, Preschool | 1 | 2018 | 3853 | 0.020 |
Why?
| | Databases, Factual | 1 | 1992 | 664 | 0.020 |
Why?
| | Middle Aged | 1 | 2023 | 11997 | 0.020 |
Why?
| | Adolescent | 1 | 2018 | 6340 | 0.020 |
Why?
| | United States | 2 | 2001 | 4838 | 0.020 |
Why?
| | Child | 1 | 2018 | 6824 | 0.020 |
Why?
| | Ventricular Fibrillation | 1 | 2001 | 16 | 0.010 |
Why?
| | Torsades de Pointes | 1 | 2001 | 15 | 0.010 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2001 | 23 | 0.010 |
Why?
| | Tachycardia, Ventricular | 1 | 2001 | 43 | 0.010 |
Why?
|
|
Corken's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|